Non-vaccinated (a) (n =21)
Vaccinated
Vaccinated
P value
1 vaccine dose (b) (n =10) 2 vaccine doses (c) (n =72)
Age, mean (SD), yr** 90.3 (7.4) 83.8 (8.4) 89.1 (7.8) 0.06
Sex, n (%)**** Female Male 15 (71.4) 6 (28.6%) 8 (80.0) 2 (20.0) 56 (77.8) 16 (22.2)
0.87
Charlson index (median, IQR) [range] **
6 (6.0-8.0) [4-15] 7.0 (5.0-8.0) 5-9 7.0 (6.0-8.0) 3-15
0.96
Prior SARS-CoV-2-positive RT-PCR, n (%)*** 1 (4.8) 0 (0) 3 (4.2) 1.00
First positive RT-PCR cycle threshold, median (IQR) **** 26.0 (23.0-32.0) 24.85 (20.4 ; 28.0) 24.00 (19.2 ; 28.6) 0.74
Cycle threshold of the second RT-PCR*, median (IQR) **** 30.3 (27-35.2) 30.7 (23.1 ; 34.5) 27.00 (21.0 ; 31.7) 0.21
Symptoms, n (%)*** Asymptomatic Mild Severe 2 (9.5) 4 (19.1) 10 (47.6) 6 (60.0) 2 (20.0) 0 31 (43.7) 23 (31.0) 15 (21.1) 0.002 0.01 (a vs b), 0.002 (a vs c) 0.09 (b vs c)
Deaths, n (%)*** 5 (23.8) 2 (20.0) 3 (4.2) 0.002 (a vs c)
SARS-CoV-2 IgG levels - N-protein IgG > 0.8 signal to cutoff ratio, n (%)** - SARS-RBD-IgG (AU/mL) ***** <50 51-1,050 1,051-4,160 >4,160 n =10 2 (20.0) 6 (60.0) 3 (30.0) 0 (0) 1 (10) n =7 1 (14.3) 1 (14.3) 5 (71.4) 1 (14.3) 0 (0) n =49 4 (8) 5 (10.2) 22 (44.9) 15 (30.6) 7 (14.3) 0.29 0.010.01 (a vs c)
Nucleocapide antigenaemia titer **, median (IQR)[range] ******
n = 7 43.0 (2.9-150.2) [0.7-555.2) n =5 1.8 (0.5-3.0) [0.2-12.5] n =37 1.5 (-0.4-16-6) [-1.5-328-4] 0.03 0.004 (a vs c)